Dsm-firmenich Raises 2026 Outlook
Dsm-firmenich reported third-quarter core profit slightly above expectations and raised its full-year growth outlook. Despite the beat, shares fell as the revised guidance was already priced in.
Xurve View
Perspectivas:
Xurve View
DSM-FIRMENICH AG posted third-quarter adjusted EBITDA of €482 million ($541.29 million) and raised its full-year sales growth outlook to 5%. The results surpassed the €478 million consensus forecast on higher contract wins across global consumer goods markets. Yet shares fell 7.5% during Wednesday morning trading because investors had already priced in the upgraded guidance.
